These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 33778041)
1. Vaccination With Recombinant Adenoviruses Expressing the Bluetongue Virus Subunits VP7 and VP2 Provides Protection Against Heterologous Virus Challenge. Rojas JM; Barba-Moreno D; Avia M; Sevilla N; Martín V Front Vet Sci; 2021; 8():645561. PubMed ID: 33778041 [TBL] [Abstract][Full Text] [Related]
2. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus. Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923 [TBL] [Abstract][Full Text] [Related]
3. Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses. Martín V; Pascual E; Avia M; Peña L; Valcárcel F; Sevilla N PLoS One; 2015; 10(11):e0143273. PubMed ID: 26619062 [TBL] [Abstract][Full Text] [Related]
11. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA. Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873 [TBL] [Abstract][Full Text] [Related]
12. CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Brun A; Anguita J; Ortego J J Virol; 2018 Aug; 92(16):. PubMed ID: 29875250 [TBL] [Abstract][Full Text] [Related]
13. An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. Ma G; Eschbaumer M; Said A; Hoffmann B; Beer M; Osterrieder N PLoS One; 2012; 7(4):e34425. PubMed ID: 22511939 [TBL] [Abstract][Full Text] [Related]
14. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2. Feenstra F; Pap JS; van Rijn PA Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389 [TBL] [Abstract][Full Text] [Related]
15. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119 [TBL] [Abstract][Full Text] [Related]
16. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep. Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203 [TBL] [Abstract][Full Text] [Related]
20. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Roy P; Bishop DH; LeBlois H; Erasmus BJ Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]